Dermatomyositis-like Eruption Induced by Hydroxyurea—Case Report and Literature Review
Abstract
:1. Introduction
2. Case Report
2.1. Clinical Examination
2.2. Routine Blood Tests Were Within Normal Limits
- CBC: No leukocytosis, hemoglobin, and platelet counts within normal range, indicating successful treatment with HU.
- Liver and Kidney Function Tests: No abnormalities.
- Inflammatory Markers: C-Reactive Protein (CRP) and Erythrocyte Sedimentation Rate (ESR) (within normal range).
- Creatine Kinase (CK) and Aldolase: Normal, ruling out significant muscle involvement.
- Autoimmune Panel: Antinuclear Antibody (ANA)-negative; myositis-specific antibodies not detected.
2.3. Histopathology and Additional Workup
2.4. Diagnosis and Management
3. Discussion
3.1. Overview of Hydroxyurea-Induced Dermatomyositis-like Eruption
3.2. Single- and Two-Patient Case Reports
- Inclusion Criteria:
- Case reports, case series, and reviews describing HU-induced DM-like eruptions.
- Studies published before 31 January 2025.
- Articles providing detailed clinical data (patient demographics, underlying condition, duration of HU therapy, clinical presentation, histopathological findings, and treatment outcomes).
- Articles available in English or with an English abstract.
- Studies retrieved from PubMed, Scopus, and Google Scholar using relevant keywords (dermatomyositis, hydroxyurea, drug-induced dermatomyositis, hydroxyurea adverse effects, cutaneous toxicity, and hydroxyurea skin reactions).
- Exclusion Criteria:
- Studies focusing on classic autoimmune DM unrelated to drug exposure.
- Cases of drug-induced DM associated with medications other than HU.
- Reports lacking detailed individual case data (e.g., broader systematic reviews or meta-analyses without specific case details).
- Non-human studies or experimental laboratory research.
3.2.1. Key Findings
3.2.2. Summary of Treatment Outcomes
3.3. Case Series and Multi-Patient Studies
3.4. Associations with Cutaneous Dysplasia and Skin Malignancies
4. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
Abbreviations
HU | Hydroxyurea |
DM | Dermatomyositis |
MPDs | Myeloproliferative disorders |
CBC | Complete Blood Count |
CRP | C-Reactive Protein |
ESR | Erythrocyte Sedimentation Rate |
CK | Creatine Kinase |
ANAs | Antinuclear Antibodies |
EMG | Electromyography |
H&E | Hematoxylin and Eosin |
AB-PAS | Alcian Blue–Periodic Acid Schiff |
DLQI | Dermatologic life quality index |
AST | Aspartate aminotransferase |
ALT | Alanine transaminase |
LDH | Lactate dehydrogenase |
MSAs | Myositis-specific autoantibodies |
MAAs | Myositis-associated antibodies |
MRI | Magnetic resonance imaging |
PDM | Paraneoplastic dermatomyositis |
CML | Chronic myeloid leukemia |
DM-LE | Dermatomyositis-like eruption |
NMSCs | Non-melanoma skin cancers |
HUSD | Hydroxyurea-associated squamous dysplasia |
SCCs | Squamous cell carcinomas |
Appendix A
Article | Patient Age/Sex | Underlying Condition | Time Since HU Initiation Until Skin Eruption | Site Affected | Case Management |
---|---|---|---|---|---|
Richard M et al. [17] | 55/F | CML and thrombocythemia | 4 years | Face, dorsal hands, buccal mucosa, lips, malleolus ulcer | HU discontinued, treated with alternative chemotherapy |
Jenerowicz D et al. [20] | 74/M | Polycythemia rubra vera | 2 years | Hands (MCP and PIP joints), periorbital area | HU discontinued, clinical resolution in 3 months |
Veraitch O et al. [21] | 40/M | Polycythemia vera | 1 month | Neck (C2-C3 dermatomes) | HU discontinued, CK improved in 2 months |
Bahadoran P et al. [22] | 62/M | CML | 5 years | Face, hands, plantar keratoderma | HU discontinued, skin lesions faded within months |
Bahadoran P et al. [22] | 58/M | CML | 7 years | Face, hands, elbows, legs | HU discontinued, moderate improvement |
Dacey M et al. [23] | 77/F | CML | 5 years | Hands (Gottron’s papules, mechanic’s hands) | HU discontinued, resolution within 6 weeks |
Daoud MS et al. [24] | 69/M | CML | 4 years | Dorsal hands, palms, elbows, dorsal feet | HU discontinued, improvement in 3 months |
de Unamuno-Bustos B et al. [25] | 76/F | Idiopathic myelofibrosis | 4 years | Dorsal hands, face, retroauricular region, periungual area, malleolus | HU discontinued, replaced with anagrelide, resolution in 10 months |
Elliott R et al. [26] | 53/M | Polycythemia rubra vera | 3 years | Dorsal hands | HU discontinued, skin started improving |
Ito E et al. [27] | 69/M | Essential thrombocytosis | 5 years | Dorsal hands, foot ulcers | HU dose reduced, lesions persisted, foot ulcer improved slightly |
Neill B et al. [28] | 67/M | Polycythemia vera | 15 years | Dorsal hands, head, trunk, extremities | HU discontinued, improvement noted |
Haniffa MA et al. [29] | 52/F | Polycythemia rubra vera | 5 years | Leg ulcers, facial rash, interphalangeal joints | HU discontinued, ulcers and skin lesions resolved |
De Unamuno B et al. [30] | 76/F | Idiopathic myelofibrosis | 4 years | Dorsal hands, face, neck | HU discontinued, replaced with anagrelide, resolution in 10 months |
Kalajian AH et al. [31] | 82/F | Dermatomyositis | 4 years | Dorsal hands | HU discontinued, treated with immunosuppressants |
Ahdoot R et al. [32] | 84/F | JAK2 + myeloproliferative neoplasm | 12 years | Dorsal hands | HU discontinued, skin biopsy confirmed dermatomyositis-like eruption |
Moreno-Artero E et al. [33] | 63/F | Essential thrombocythemia | 3 years | Dorsal hands, feet, elbows, knees, presternal area | HU continued, lesions persisted |
Nofal A et al. [34] | 68/F | CML | 6 years | Dorsal hands, face, nails, tongue, soles, heels | HU stopped, replaced by busulfan, improvement within 3–6 months |
Sanchez-Palacios C et al. [35] | 69/M | Essential thrombocythemia | 9 years | Face, forearms, back of hands | HU discontinued, failed trial of anagrelide, restarted HU |
Sanchez-Palacios C et al. [35] | 66/M | CML | 11 years | Scalp, multiple cutaneous cancers | HU continued, isotretinoin started |
Slobodin G et al. [36] | 57/F | CML | 3 years | Dorsal hands, forearms | HU discontinued, patient died of coronary event |
Suehiro M et al. [37] | 52/F | CML | 5 years | Dorsal hands, fingers, telangiectasia, ulcers | HU discontinued, improvement within 4 weeks |
Varma S et al. [38] | 81/F | Psoriasis | 59 months | Dorsal hands, periungual telangiectasia | HU continued, lesions persisted |
Zappala TM et al. [39] | 66/F | Myelofibrosis | 5 years | Dorsal hands, severe xerosis, palmar erythema, ulcers | HU discontinued, slow improvement over 6 months |
Article | Number of Cases | Patient Age/Sex | Underlying Condition | Time Since HU Initiation Until Skin Eruption | Site Affected and Case Management |
---|---|---|---|---|---|
Vassallo C et al. [8] | 7 | Mean age 57 (range 25–73) 5 M/2 F | 7/7 CML | 2.5 years (range 7 to 60 months) | Acral erythema, xerosis, ichthyosiform lesions, telangiectases, ulcers of both heels, DM-like changes. HU was discontinued in all patients; resolution of skin lesions in 9 months average (range 4–24 months). |
Sennet P et al. [18] | 6 | Mean age 69 (range 47–66) 3 M/3 F | 4/6 CML 2/6 essential thrombocythemia | 5.3 years (range 2–10) | Interphalangeal and metacarpophalangeal joints of the hands, and on the dorsal region of the feet. HU withdrawal led to lesion resolution within 1 to 6 months in three cases, while lesions persisted in two patients who continued treatment. |
Yu K et al. [40] | 8 | Mean age 68 (range not specified) 4 M/4 F | CML and thrombocythemia | 5.5 years (range not specified) | Heliotrope sign, poikiloderma, Gottron sign, mechanic’s hands. Not specified. |
Oh ST et al. [41] | 7 | Mean age 43 (range 16–54) 4 M/3 F | 7/7 CML | 1 year (range 6 months to 4 years) | Melanonychia in all patients; two developed DM-like eruptions on sites not specified. Topical and intralesional corticosteroids, with mild improvement after 1 month. |
References
- Boyd, A.S.; Kenneth, H.; Neldner, M.D. Hydroxyurea therapy. J. Am. Acad. Dermatol. 1991, 25, 518–524. [Google Scholar] [CrossRef] [PubMed]
- Simeonovski, V.; Breshkovska, H.; Duma, S.; Dohcheva-Karajovanov, I.; Damevska, K.; Nikolovska, S. Hydroxyurea-associated cutaneous lesions: A case report. Open Access Maced. J. Med. Sci. 2018, 6, 1458–1461. [Google Scholar] [CrossRef]
- McGann, P.T.; Ware, R.E. Hydroxyurea therapy for sickle cell anemia. Expert Opin. Drug Saf. 2015, 14, 1749–1758. [Google Scholar] [CrossRef] [PubMed]
- Yarbro, J.W. Mechanism of action of hydroxyurea. Semin. Oncol. 1992, 19 (Suppl. 9), 1–10. [Google Scholar]
- Kumar, B.; Saraswat, A.; Kaur, I. Mucocutaneous adverse effects of hydroxyurea: A prospective study of 30 psoriasis patients. Clin. Exp. Dermatol. 2002, 27, 8–13. [Google Scholar] [CrossRef] [PubMed]
- O’Branski, E.E.; Ware, R.E.; Prose, N.S.; Kinney, T.R. Skin and nail changes in children with sickle cell anemia receiving hydroxyurea therapy. J. Am. Acad. Dermatol. 2001, 44, 859–861. [Google Scholar] [CrossRef]
- Kennedy, B.J.; Smith, L.R.; Goltz, R.W. Skin changes secondary to hydroxyurea therapy. Arch. Dermatol. 1975, 111, 183–187. [Google Scholar] [CrossRef]
- Vassallo, C.; Passamonti, F.; Merante, S.; Ardigo, M.; Nolli, G.; Mangiacavalli, S.; Borroni, G. Muco-cutaneous changes during long-term therapy with hydroxyurea in chronic myeloid leukaemia. Clin. Exp. Dermatol. 2001, 26, 141–148. [Google Scholar] [CrossRef]
- Antonioli, E.; Guglielmelli, P.; Pieri, L.; Finazzi, M.; Rumi, E.; Martinelli, V.; Vianelli, N.; Bertozzi, I.; De Stefano, V.; Za, T.; et al. Hydroxyurea-related toxicity in 3,411 patients with Ph’-negative MPN. Am. J. Hematol. 2012, 87, 552–554. [Google Scholar] [CrossRef]
- Chaine, B.; Neonato, M.G.; Girot, R.; Aractingi, S. Cutaneous adverse reactions to hydroxyurea with sickle cell disease. Arch. Dermatol. 2001, 137, 467–470. [Google Scholar]
- Salmon-Ehr, V.; Leborgne, G.; Vilque, J.P.; Potron, G.; Bernard, P. Secondary cutaneous effects of hydroxyurea: Prospective study of 26 patients from a dermatologic consultation. Rev. Med. Interne 2000, 21, 30–34. [Google Scholar] [CrossRef] [PubMed]
- Bohan, A.; Peter, J.B. Polymyositis and dermatomyositis—(First of two parts). N. Engl. J. Med. 1975, 292, 344–347. [Google Scholar] [CrossRef] [PubMed]
- Cheeti, A.; Brent, L.H.; Panginikkod, S. Autoimmune Myopathies; StatPearls Publishing LLC: Treasure Island, FL, USA, 2024. [Google Scholar]
- Didona, D.; Juratli, H.A.; Scarsella, L.; Eming, R.; Hertl, M. The polymorphous spectrum of dermatomyositis: Classic features, newly described skin lesions, and rare variants. Eur. J. Dermatol. 2020, 30, 229–242. [Google Scholar] [CrossRef]
- Waldman, R.; DeWane, M.E.; Lu, J. Dermatomyositis: Diagnosis and treatment. J. Am. Acad. Dermatol. 2020, 82, 283–296. [Google Scholar] [CrossRef]
- Leatham, H.; Schadt, C.; Chisolm, S.; Fretwell, D.; Chung, L.; Callen, J.P.; Fiorentino, D. Evidence supports blind screening for internal malignancy in dermatomyositis: Data from two large US dermatology cohorts. Medicine 2018, 97, e9639. [Google Scholar] [CrossRef]
- Richard, M.; Truchetet, F.; Friedel, J.; Leclech, C.; Heid, E. Skin lesions simulating chronic dermatomyositis during long-term hydroxyurea therapy. J. Am. Acad. Dermatol. 1989, 21 Pt 1, 797–799. [Google Scholar] [CrossRef] [PubMed]
- Sennet, P.; Aractingi, S.; Porneuf, M.; Perrin, P.; Duterque, M. Hydroxyurea-induced dermatomyositis-like eruption. Br. J. Dermatol. 1995, 133, 455–459. [Google Scholar] [CrossRef]
- Caravan, S.; Lopez, C.M.; Yeh, J.E. Causes and clinical presentation of drug-induced dermatomyositis: A systematic review. JAMA Dermatol. 2024, 160, 210–217. [Google Scholar] [CrossRef]
- Janerowicz, D.; Czarnecka-Operacz, M.; Stawny, M.; Silny, W. Dermatomyositis-like eruption induced by hydroxyurea: A case report. Acta Dermatovenerol. Alp. Panon. Adriat. 2009, 18, 131–134. [Google Scholar]
- Veraitch, O.; Curto-Garcia, N.; Harrison, C.; Stefanato, C.M.; McGibbon, D. Hydroxyurea-induced dermatomyositis koebnerizing at the site of previous shingles. Clin. Exp. Dermatol. 2019, 44, 546–548. [Google Scholar] [CrossRef]
- Bahadoran, P.; Castanet, J.; Lacour, J.P.; Perrin, C.; Del Giudice, P.; Mannocci, N.; Fuzibet, J.G.; Ortonne, J.P. Pseudo-dermatomyositis induced by long-term hydroxyurea therapy: Report of two cases. Br. J. Dermatol. 1996, 134, 1161–1163. [Google Scholar] [CrossRef]
- Dacey, M.J.; Callen, J.P. Hydroxyurea-induced dermatomyositis-like eruption. J. Am. Acad. Dermatol. 2003, 48, 439–441. [Google Scholar] [CrossRef] [PubMed]
- Daoud, M.S.; Gibson, L.E.; Pittelkow, M.R. Hydroxyurea dermopathy: A unique lichenoid eruption complicating long-term therapy with hydroxyurea. J. Am. Acad. Dermatol. 1997, 36 Pt 1, 178–182. [Google Scholar] [CrossRef]
- de Unamuno-Bustos, B.; Ballester-Sánchez, R.; Sabater Marco, V.; Vilata-Corell, J.J. Dermatomyositis-like eruption associated with hydroxyurea therapy: A premalignant condition? Actas Dermo-Sifiliogr. 2014, 105, 876–878. [Google Scholar]
- Elliott, R.; Davies, M.; Harmse, D. Dermatomyositis-like eruption with long-term hydroxyurea. J. Dermatol. Treat. 2006, 17, 59–60. [Google Scholar]
- Ito, E.; Muro, Y.; Shibata, A.; Sugiura, K.; Akiyama, M. Hydroxyurea-induced amyopathic dermatomyositis presenting with heliotrope erythema. Dermatol. Online J. 2014, 20. [Google Scholar] [CrossRef]
- Neill, B.; Ryser, T.; Neill, J.; Aires, D.; Rajpara, A. A patient case highlighting the myriad of cutaneous adverse effects of prolonged use of hydroxyurea. Dermatol. Online J. 2017, 23. [Google Scholar] [CrossRef]
- Haniffa, M.A.; Speight, E.L. Painful leg ulcers and a rash in a patient with polycythaemia rubra vera. Diagnosis: Hydroxyurea-induced leg ulceration and dermatomyositis-like skin changes. Clin. Exp. Dermatol. 2006, 31, 733–734. [Google Scholar]
- De Unamuno, B.; Vilata Corell, J.J.; Ballester Sanchez, R.; Alegre Miquel, V. Hydroxyurea-induced dermatomyositis-like eruption with abnormal expression of p53. J. Am. Acad. Dermatol. 2013, 68, AB70. [Google Scholar]
- Kalajian, A.H.; Cely, S.J.; Malone, J.C.; Burruss, J.B.; Callen, J.P. Hydroxyurea-associated dermatomyositis-like eruption demonstrating abnormal epidermal p53 expression: A potential premalignant manifestation of chronic hydroxyurea and UV radiation exposure. Arch. Dermatol. 2010, 146, 305–310. [Google Scholar] [CrossRef]
- Ahdoot, R.; Rew, J.; Reynolds, K.A.; Lowe, L.; Mervak, J.E. Violaceous scaly plaques of the dorsal hands. JAAD Case Rep. 2024, 49, 85–87. [Google Scholar] [CrossRef] [PubMed]
- Moreno-Artero, E.; Paricio, J.J.; Antoñanzas, J.; España, A. Dermatomyositis-like Eruption in a Woman Treated with Hydroxyurea. Actas Dermo-Sifiliogr. (Engl. Ed.) 2019, 110, 64–67. [Google Scholar] [CrossRef]
- Nofal, A.; El-Din, E.S. Hydroxyurea-induced dermatomyositis: True amyopathic dermatomyositis or dermatomyositis-like eruption? Int. J. Dermatol. 2012, 51, 535–541. [Google Scholar] [CrossRef]
- Sanchez-Palacios, C.; Guitart, J. Hydroxyurea-associated squamous dysplasia. J. Am. Acad. Dermatol. 2004, 51, 293–300. [Google Scholar] [CrossRef] [PubMed]
- Slobodin, G.; Lurie, M.; Munichor, M.; Kovalev, J.; Rosner, I. Gottron’s papules-like eruption developing under hydroxyurea therapy. Rheumatol. Int. 2006, 26, 768–770. [Google Scholar] [CrossRef] [PubMed]
- Suehiro, M.; Kishimoto, S.; Wakabayashi, T.; Ikeuchi, A.; Miyake, H.; Takenaka, H.; Okano, A.; Hirai, H.; Shimazaki, C.; Yasuno, H. Hydroxyurea dermopathy with a dermatomyositis-like eruption and a large leg ulcer. Br. J. Dermatol. 1998, 139, 748–749. [Google Scholar] [CrossRef]
- Varma, S.; Lanigan, S.W. Dermatomyositis-like eruption and leg ulceration caused by hydroxyurea in a patient with psoriasis. Clin. Exp. Dermatol. 1999, 24, 164–166. [Google Scholar] [CrossRef]
- Zappala, T.M.; Rodins, K.; Muir, J. Hydroxyurea induced dermatomyositis-like eruption. Australas. J. Dermatol. 2012, 53, e58–e60. [Google Scholar] [CrossRef]
- Yu, K.; Wang, T.; An, D.; Li, X.; Tang, Z. Investigating the disparities among drug categories in drug-induced dermatomyositis: A systematic review. Semin. Arthritis Rheum. 2024, 67, 152478. [Google Scholar] [CrossRef]
- Oh, S.T.; Lee, D.W.; Lee, J.Y.; Cho, B.K. Hydroxyurea-induced melanonychia concomitant with a dermatomyositis-like eruption. J. Am. Acad. Dermatol. 2003, 49, 339–341. [Google Scholar] [CrossRef]
- Schleußinger, T.M.; Dyall-Smith, D.; Field, L.M. Hydroxyurea-associated squamous dysplasia in a monozygotic twin. J. Am. Acad. Dermatol. 2011, 65, 679–680. [Google Scholar] [CrossRef] [PubMed]
- Grandi, V.; Delfino, C.; Pimpinelli, N. Ingenol mebutate in the treatment of ‘Hydroxyurea-induced Squamous Dysplasia’: A single-centre experience. J. Eur. Acad. Dermatol. Venereol. 2016, 30, 1129–1133. [Google Scholar] [CrossRef]
- De Benedittis, M.; Petruzzi, M.; Giardina, C.; Lo Muzio, L.; Favia, G.; Serpico, R. Oral squamous cell carcinoma during long-term treatment with hydroxyurea. Clin. Exp. Dermatol. 2004, 29, 605–607. [Google Scholar] [CrossRef] [PubMed]
- Antar, A.; Ishak, R.S.; Otrock, Z.K.; El-Majzoub, N.; Ghosn, S.; Mahfouz, R.; Taher, A.T. Successful treatment of hydroxyurea-associated chronic leg ulcers associated with squamous cell carcinoma. Hematol. Oncol. Stem Cell Ther. 2014, 7, 166–169. [Google Scholar] [CrossRef] [PubMed]
- Horn, M.A.; Gordon, K.B. Chemoprevention of skin cancer. In Cancer Chemoprevention; Bergan, R.C., Ed.; Kluwer Academic Publishers: Norwell, MA, USA, 2001; pp. 255–282. [Google Scholar]
- McKenna, D.B.; Murphy, G.M. Skin cancer chemoprophylaxis in renal transplant recipients: 5 years of experience using low-dose acitretin. Br. J. Dermatol. 1999, 140, 656–660. [Google Scholar] [CrossRef]
- George, R.; Weightman, W.; Russ, G.R.; Bannister, K.M.; Mathew, T.H. Acitretin for chemoprevention of non-melanoma skin cancers in renal transplant recipients. Australas. J. Dermatol. 2002, 43, 269–273. [Google Scholar] [CrossRef]
- DiGiovanna, J.J. Retinoid chemoprevention in patients at high risk for skin cancer. Med. Pediatr. Oncol. 2001, 36, 564–567. [Google Scholar] [CrossRef]
Feature | Hydroxyurea-Induced DM-like Eruption | Classic Autoimmune Dermatomyositis |
---|---|---|
Etiology | Drug-induced (hydroxyurea exposure) | Autoimmune-mediated, often associated with myositis-specific antibodies |
Cutaneous Manifestations | DM-like rash (Gottron’s papules, heliotrope rash, poikiloderma, periungual changes) | Similar rash distribution but often more widespread |
Muscle Involvement | Absent | Present in most cases, with proximal muscle weakness |
Serological Markers | Negative for myositis-specific antibodies | Often positive for anti-Mi-2, anti-TIF1-γ, anti-MDA5, anti-Jo-1 antibodies |
Histopathology | Interface dermatitis, basal vacuolar degeneration, dermal mucin deposition | Similar findings, but often with more prominent inflammation and vasculopathy |
Association with Malignancy | Possible, particularly with long-term HU exposure | Strong association, particularly with anti-TIF1-γ positive cases |
Treatment | Discontinuation of HU, corticosteroids, immunosuppressants if needed | Systemic corticosteroids, immunosuppressants, IVIG, and other DM-specific therapies |
Prognosis | Good with HU discontinuation; lesions usually resolve within months | Variable; can be chronic and relapsing, especially with muscle involvement |
Feature | Findings |
---|---|
Total number of cases reviewed | 23 cases |
Mean patient age (years) | 67 years |
Female-to-male ratio | 13:10 |
Median latency period (years) | 5 years |
Most commonly affected sites | Dorsal hands, face, periungual region |
Percentage with periorbital involvement | 43.5% (10/23 cases) |
Percentage with dorsal hand involvement | 91.3% (21/23 cases) |
Percentage with nail involvement | 69.6% (16/23 cases) |
Percentage with histopathological DM-like features | 100% |
Percentage who discontinued HU | 91.3% (21/23 cases) |
Median resolution time after HU discontinuation (months) | 3 months (range: 10 days–10 months) |
Treatment Approach | Number of Cases | Outcome |
---|---|---|
HU discontinuation | 21/23 cases (91.3%) | Complete or near-complete resolution |
Dose reduction without discontinuation | 2/23 cases (8.7%) | Lesions persisted but partially improved |
Topical corticosteroids alone | All cases received topical corticosteroids | Used adjunctively; limited standalone efficacy |
Systemic corticosteroids | 12/23 cases (52.2%) | Accelerated improvement; used in moderate–severe cases |
Steroid-sparing agents (e.g., azathioprine and methotrexate) | 5/23 cases (21.7%) | Allowed steroid tapering; prevented relapses in some cases |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Stoica, L.E.; Mitroi, M.R.; Ică, O.M.; Vîlcea, A.M.; Fronie-Andrei, L.P.; Vîlcea, C.I.; Ciurea, R.N.; Mihai, A.; Mitroi, G.G. Dermatomyositis-like Eruption Induced by Hydroxyurea—Case Report and Literature Review. J. Clin. Med. 2025, 14, 2192. https://doi.org/10.3390/jcm14072192
Stoica LE, Mitroi MR, Ică OM, Vîlcea AM, Fronie-Andrei LP, Vîlcea CI, Ciurea RN, Mihai A, Mitroi GG. Dermatomyositis-like Eruption Induced by Hydroxyurea—Case Report and Literature Review. Journal of Clinical Medicine. 2025; 14(7):2192. https://doi.org/10.3390/jcm14072192
Chicago/Turabian StyleStoica, Loredana Elena, Mihaela Roxana Mitroi, Oana Maria Ică, Alina Maria Vîlcea, Lavinia Petruța Fronie-Andrei, Cristina Ioana Vîlcea, Raluca Niculina Ciurea, Andreea Mihai, and George G. Mitroi. 2025. "Dermatomyositis-like Eruption Induced by Hydroxyurea—Case Report and Literature Review" Journal of Clinical Medicine 14, no. 7: 2192. https://doi.org/10.3390/jcm14072192
APA StyleStoica, L. E., Mitroi, M. R., Ică, O. M., Vîlcea, A. M., Fronie-Andrei, L. P., Vîlcea, C. I., Ciurea, R. N., Mihai, A., & Mitroi, G. G. (2025). Dermatomyositis-like Eruption Induced by Hydroxyurea—Case Report and Literature Review. Journal of Clinical Medicine, 14(7), 2192. https://doi.org/10.3390/jcm14072192